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establishing now in Ukraine. Methods: We performed a retrospective analy-
sis of the real data from 450 medical records of patients who were treated 
in a Lviv Regional Perinatal Center in 2013. The results of our previous study of 
treatment cost of endometriosis in Ukraine were used (Zalis’ka O., Piniazhko O. 
et al. 2014). We used the prices from Ukrainian database of Morion company 
(Kiev) on 01.06.2014 (1 EUR = 16,04 UAH). Results: According to the analysis 
70% of women with endometriosis choose treatment hormones with the dura-
tion of six month usually and 30% of patients undergo surgical treatment. 
Annual direct cost of endometriosis per patient varies from € 224 to € 487 depending 
on the chosen scheme of pharmacotherapy, which differences 2 times. Accordingly, 
costs correlated with clinical severity and patient’s financial position and ability to 
pay. Based on the data of State Statistics Service of Ukraine, we estimated that the 
number of women of reproductive age in Ukraine was 14,7 million in 2013. Therefore 
when to extrapolate data the number of women with endometriosis could amount 
approximately 1,47 million and 1,03 million women would take pharmacotherapy 
instead of surgery. The annual cost of treatment hormones of endometriosis could 
amount from € 230,5 million to € 501,6 million. ConClusions: The economic burden 
of endometriosis in Ukraine demonstrates a significant need in the optimization of 
the management of this disease within the introduction of health insurance system 
and health technology assessment of the applicable hormones.
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objeCtives: Life expectancy in Italy is constantly increasing (+2,4 years for men and 
+1,7 years for women from 2001 to 2011) with a consequent effect on health needs 
and expenditure. Furthermore, on overall population, 21% has one chronic disease, 
9,3% two and 8% more than three. The aim of this study is to evaluate the burden 
of multiple chronic diseases and associated costs in a large community setting 
of Italian elderly population, starting from Cineca ARNO Observatory. Methods: 
ARNO Observatory is a comprehensive population-based database which integrates 
since 1987 administrative data from Local Health Units to monitor health data 
in the real world. On a population of 10,5 millions of inhabitants we selected a 
cohort of 2.166.000 (21%) subjects over 65 years. Outpatient drug prescriptions, inpa-
tient hospital discharges, diagnostic, lab tests prescriptions were analyzed during 
2012 to evaluate chronic diseases, multiple chronic conditions and illness direct 
costs. Results: From selected cohort, 82,5% has at least one chronic disease and 
this proportion rises up to 89,6% in over 80s. Hypertension is the most common 
disease (67%), followed by dyslipidemia (30%) and diabetes (18%). Over 50% of elderly 
has multiple chronic diseases but the risk of developing concomitant chronic ill-
nesses rises with ages (60% of people aged > = 85 have comorbidities). Integration 
of administrative data led to the evaluation of cost of illness which varies from 
2.528€ for hypertension to 13.613€ for Acute Coronary Syndrome; the average cost of 
patients with 2 or more comorbidities is twice than patients with only one chronic 
disease. In general, more than a half of cost is due to hospitalization (57%), 27% to 
drugs and 16% to diagnostic exams (16%). ConClusions: Analyses of real world 
data represent an effective tool for the evaluation of elderly population diseases 
and can be a valid instrument to support clinical governance.
PIH19
ePIdeMIologICal and fInanCIal Burden of PreterM laBor 
HosPItalIzatIons – an analysIs of gerMan ClaIMs data
Wetzka S.1, Fleßa S.1, Lange A.2, Zygmunt M.3
1Department of Health Care Management, Faculty of Law and Economics, Ernst-Moritz-Arndt-
University Greifswald, Greifswald, Germany, 2Department of Neonatology and Pediatric Intensive 
Care, Hospital for Pediatrics, University of Greifswald, Greifswald, Germany, 3Department of 
Obstetrics and Gynecology, University of Greifswald, Greifswald, Germany
objeCtives: Preterm Labor (PTL) in pregnant women is a common obstetrics inpa-
tient diagnosis. It is important to differentiate between threatened PTL associated 
with potentially avoidable hospitalization and PTL resulting in a preterm birth (PTB) 
with respect to their burden to the health care system. The prevention and diag-
nostic-driven reduction of such hospital admissions for observational reasons are 
supposed to reduce costs. The aim is to analyze the epidemiological and financial 
impact of programs to prevent avoidable hospital admissions due to threatened 
PTL. Methods: A cohort of singletons at the University hospital Greifswald with 
PTL-related hospital admissions prior to birth was analyzed with respect to resource 
use and obstetrics outcomes. This bottom-up analysis was conducted from the 
perspective of the statutory health care system based on accounting information 
claims from the hospital`s database for the period 2007 to 2012. ICD-10 codes were 
used to identify the study population. All costs were inflated to 2012 using the 
German GDP index. Results: Out of 4,408 singleton births, potentially avoidable 
hospital admissions were found in 248 cases (5.6 %). In this subgroup, 17 infants 
were delivered preterm (avg. 34.8 weeks), resulting in a PTB rate of 6.9 % compared 
to a general rate of 8.7 % in Germany. These hospitalizations led to average costs of 
about 1,600 EUR per case (min. 300 EUR; max. 5,600 EUR). ConClusions: Although 
threatened PTL affects one singleton pregnancy in 20, the fraction of costs result-
ing from observational admissions associated with threatened PTL is less than 0.7 
percent compared to the total department costs. This finding conflicts with the 
cost-saving potential of prevention programs (e. g. pH self-assessment) suggested 
in the literature.
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between 2001 and 2012. One study was on early screening using maternal markers, 
and concluded that this may be cost-effective from a payer perspective. Three other 
studies focused on treatment and management, and concluded that induction of 
delivery is the most cost-effective option in term preeclampsia. Also, magnesium 
sulphate was found to be a cost-effective treatment, but more so in low income 
countries. One study was a comprehensive HTA report on combination strategies 
of screening and prevention, which found that providing calcium to all pregnant 
women without prior testing was the most cost-effective strategy. The BIA, on intro-
ducing a novel diagnostic test, concluded that the savings associated with this test 
would offset its initial cost. ConClusions: Novel biomarkers in screening for and 
diagnosing preeclampsia show promise as a cost-effective approach, from a payer 
perspective. Moreover, magnesium sulphate seemed to be a cost-effective option 
to manage seizures in preeclamptic women while delivery remains the ultimate 
efficient treatment, especially for women with term preeclampsia.
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objeCtives: To determine and quantify the level of price variation in inpatient care 
for obstetrical services across hospitals in the State of Vermont, USA. Methods: 
We used data from Vermont Healthcare Claims Uniform Reporting and Evaluation 
System (VHCURES) for the calendar year 2012. We generated single-line summaries 
for all inpatient obstetrical services with an admission date in 2012. We excluded 
records for Medicaid, secondary payments either to Medicare or another commer-
cial insurance, denied claims, non-VT resident claims and adjustments to existing 
claims. This produced a total of 4,019 records for the evaluated services from 13 
Vermont hospitals. We calculated the allowed amount for each Diagnosis Related 
Group (DRG) (total amount a hospital received from a payer, including any prepaid 
amounts related to the service, plus the amount due from a patient through copay-
ment, co-insurance and deductible). The outcome of interest is the average price 
of a specific DRG at each hospital as a percent of group average price in Vermont 
Hospitals. To reflect patient severity we adjusted prices by case-mix. Results were 
generated for hospitals only when there were at least 10 discharges in a specific 
hospital. Results: The average prices for a vaginal delivery with complicating diag-
noses varied between 66% to 156% of the group average, vaginal delivery without 
complicating diagnoses varied between 74% to 182%, neonate with other significant 
problems varied between 60% to 206% and normal newborn varied between 77% to 
180%. ConClusions: There is wide variation in payments for obstetrical services 
across Vermont hospitals. Further analysis is necessary to understand the role of 
various factors that contribute to this variation. During this transition period to a 
single-payer system in the rural state of Vermont, policy makers will need evidence-
based information to ensure undiminished access to care in obstetrical services.
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objeCtives: To estimate the economic impact of malnutrition on annual direct 
cost in Spanish institutionalized or community-dwelling older adults. Methods: 
A systematic review was carried out on the economic burden and use of medi-
cal resources associated with malnutrition in institutionalized or community-
dwelling older adults. National and international databases until December 2013 
were searched. Based on results from the literature review, an Excel-based tool 
was developed to estimate the annual cost difference between malnourished and 
well-nourished institutionalized and community-dwelling older adults in Spain. 
Malnutrition prevalence, annual frequency of general practitioner (GP) visits and 
hospitalizations were the main inputs considered in the model. Unit costs were 
derived from health care cost databases available in Spain (Euros, 2014). One-way 
sensitivity analysis (OWSA) was performed. Results: The results of the systematic 
review showed that malnutrition implies higher medical costs in the study popula-
tion, particularly due to the length of hospital stay, number of hospital admissions 
and GP visits. Economic results showed that the annual cost associated with the 
use of resources of a malnourished patient (€ 5,000.66) was 3.5 times higher than 
that of a well-nourished (€ 1,433.78). OWSA showed that prevalence of malnutrition 
was the variable with the greatest impact on results. Decreasing the prevalence 
of malnutrition according to minimum values identified in the literature (from 
15.6% and 4.4%, to 2% and 3% in institutionalized and community-dwelling patients 
respectively), caused the annual cost per patient with malnutrition to drop from 
€ 5,000.66 to € 2,511.83, while increasing it to the maximum values (62% and 23%, 
respectively), implied a rise from € 5,000.66 to € 24,291.93 in the annual cost per 
patient. ConClusions: Adopting measures to reduce the prevalence of malnu-
trition in institutionalized or community-dwelling older adults would reduce by 
up to 50% the annual cost per patient associated to GP visits and hospitalizations.
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objeCtives: Endometriosis affects 10% of women of reproductive age and WERF 
EndoCost study has recently shown that it imposes substantial economic burden 
on society through the reduced economic and personal productivity. The aim of 
the study was to estimate the prevalence of endometriosis and the cost of ill-
ness from the payer’s perspective in Ukraine as the model of health insurance is 
